UCB's Global Corporate Website

UCB delivers strong results

Posted by
Antje Witte, Investor Relations
We’ve had a busy week preparing for the release of our half-yearly results and we are pleased with UCB's strong financial results reported today.

In the first half of 2011, UCB’s total revenue increased by 2% to €1,679 million and we were particularly delighted to see sales of our new medicines (Cimzia®, Vimpat®, Neupro®) grow by 61% in total.

During hectic spells like this, it’s rewarding to take stock of the fact that our new drugs have already touched the lives of more than 248,000 patients worldwide.

It’s reassuring to see the solid financials of the company and we are also encouraged by the strong R&D pipeline which has strengthened in the first half of the year and is showing promise in some key areas.

So the first half of the year delivered strong financial results and shows good momentum of our new core medicines, a strengthened pipeline with potential UCB new medicines and from 2012 onward, we do expect a decade without impacts from major patent expirations.

Overall though, where each of us at UCB finds great motivation is in thinking of the people behind those numbers.

Click here to read more details of the half-year report